Recording of non-operating expenses and extraordinary losses
Carna Biosciences,Inc. (the company)
Amortization of issuance discounts arising upon the issuance of convertible bonds with share acquisition rights and bonds, interest on convertible bonds with share acquisition rights, exchange-rate movements, and the write-down of assets showing indications of impairment to their recoverable amounts
As non-operating expenses, the company recorded ¥19.108 million in interest expenses and ¥4.451 million in bond issuance costs during the third-quarter consolidated accounting period. Foreign exchange gains of ¥4.267 million were recognized, resulting in cumulative foreign exchange losses of ¥4.845 million for the nine-month consolidated period. As an extraordinary loss, the company recorded ¥7.406 million in impairment losses during the third-quarter consolidated accounting period, bringing the cumulative amount recognized for the nine-month consolidated period to ¥19.757 million.
Third-quarter consolidated accounting period of the fiscal year ending December 2026 (1 July 2026 to 30 September 2026), and nine-month consolidated period (1 January 2026 to 30 September 2026)
| Item | Details |
|---|---|
| Event name | Recording of non-operating expenses and extraordinary losses |
| Date of occurrence | 1 July 2026 to 30 September 2026 (third-quarter consolidated accounting period) |
| Subject Entity | Carna Biosciences,Inc. (the company) |
| Cause | Amortization of issuance discounts arising upon the issuance of convertible bonds with share acquisition rights and bonds, interest on convertible bonds with share acquisition rights, exchange-rate movements, and the write-down of assets showing indications of impairment to their recoverable amounts |
| Amount of Impact on Business Performance | As non-operating expenses, the company recorded ¥19.108 million in interest expenses and ¥4.451 million in bond issuance costs during the third-quarter consolidated accounting period. Foreign exchange gains of ¥4.267 million were recognized, resulting in cumulative foreign exchange losses of ¥4.845 million for the nine-month consolidated period. As an extraordinary loss, the company recorded ¥7.406 million in impairment losses during the third-quarter consolidated accounting period, bringing the cumulative amount recognized for the nine-month consolidated period to ¥19.757 million. |
| Accounting period in which recognized | Third-quarter consolidated accounting period of the fiscal year ending December 2026 (1 July 2026 to 30 September 2026), and nine-month consolidated period (1 January 2026 to 30 September 2026) |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Interest expenses consisted of the amortization of issuance discounts arising upon the issuance of convertible bonds with share acquisition rights and bonds, and interest on the convertible bonds with share acquisition rights. The decrease in foreign exchange losses resulted from foreign exchange gains arising from exchange-rate movements, while impairment losses were recognized because assets showing indications of impairment were written down to their recoverable amounts.